In the midst of a controversy surrounding a 40-year old Chennai subject in the clinical trial in India of the Oxford-AstraZeneca vaccine falling seriously ill and demanding Rs 5 crore in damages from Pune based Serum Institute of India (SII), the firm on Tuesday assured that the vaccine candidate Covishield is safe and that it would not released for mass use unless proven 'immunogenic and safe'.
Addressing the concerns related to the adverse reaction reported by the volunteer in Chennai, SII said, "The Covishield vaccine is safe and immunogenic. The incident with the Chennai volunteer though highly unfortunate was in no way induced by the vaccine and Serum Institute of India is sympathetic with the volunteer's medical condition."
The spokesperson added, "However, we would like to clarify that all the requisite regulatory and ethical processes and guidelines were followed diligently and strictly. The concerned authorities were informed and the principal investigator, Drug Safety Monitoring Board (DSMB) and the Ethics Committee independently cleared and reckoned it as a non-related issue to the vaccine trial, post which we submitted all the reports and data related to the incident to the DCGI."
SII further clarified that it was only after it 'cleared' all the required processes that it continued with the trial.
"We would want to assure everyone that the vaccine won’t be released for mass use unless it is proven immunogenic, and safe. Taking into consideration the complexities and existing misnomers about vaccination and immunisation; the legal notice was sent therefore to safeguard the reputation of the company which is being unfairly maligned," the company added.
The DCGI is now carrying out an in-depth investigation of the documents submitted by SII.
The volunteer who suffered neurological illness and was hospitalised for more than a week had sent a legal notice to the company seeking Rs 5 crore in damages. His lawyers have indicated that the participant has not received any formal communication from the company saying that his illness (acute encephalopathy) is unrelated to the vaccine. Moreover, the law firm Advocates Row & Reddy and R Rajaram, who sent a legal notice on behalf of the 40-year-old individual, has claimed that the sponsor of the trial or SII has not borne the medical expenses he incurred. In response, SII had said that the allegations are 'malicious and misconceived' and that it would seek Rs 100 crore in damages.
Experts had found the response disappointing. Dr Shahid Jameel, senior virologist and director at Ashoka University told Business Standard that he found the response 'disappointing'.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU